If your kidneys could not produce erythropoietin (EPO), your body would gradually lose the ability to make new red blood cells. Without this hormone, red blood cell precursors in the bone marrow would die before maturing, oxygen delivery to every organ would drop, and a progressive, potentially life-threatening anemia would develop. This is not a hypothetical scenario: it happens every day in people with advanced kidney disease.
How the Kidneys Normally Make EPO
EPO is produced by specialized cells in the kidneys called pericytes, which wrap around tiny blood vessels deep in the kidney tissue. These cells act as oxygen sensors. When oxygen levels in the blood drop even slightly, a protein called hypoxia-inducible factor (HIF) activates inside the pericytes and switches on the EPO gene, ramping up production. Once released into the bloodstream, EPO travels to the bone marrow with a simple message: make more red blood cells.
The system is remarkably responsive. A healthy person’s EPO levels sit around 3 to 18 IU/L, but when the body detects anemia or low oxygen, those levels can spike exponentially. In people with damaged kidneys, this relationship breaks down. Their EPO levels may not technically be “low” by a lab’s reference range, but they are inappropriately low for the degree of anemia present. The kidneys simply cannot mount the surge the body needs.
What Happens in the Bone Marrow Without EPO
Red blood cells begin as immature progenitor cells in the bone marrow. EPO’s job is twofold: it tells these progenitors to multiply and mature, and it actively protects them from a built-in self-destruct program. Without sufficient EPO, erythroid progenitors activate a cell-death sequence. Their mitochondria lose function, enzymes called caspases go unchecked, and a critical protein needed for red blood cell development (GATA1) gets destroyed. The result is that these precursor cells die before ever becoming functional red blood cells.
This means EPO is not just a growth signal. It is a survival signal. The fate of every developing red blood cell depends on whether enough EPO is present to tip the balance toward maturation rather than self-destruction. When the kidneys fail to produce it, the bone marrow still contains the raw materials for blood production, but it cannot use them.
Symptoms of EPO Deficiency
The consequences show up as classic anemia symptoms, driven by the simple fact that fewer red blood cells means less oxygen reaching your tissues. The most common signs include persistent fatigue and weakness, shortness of breath during ordinary activities, dizziness, difficulty concentrating, pale skin, chest pain, and an unusual sensitivity to cold. These symptoms tend to develop gradually as kidney function declines, which is why many people attribute them to aging or stress before anemia is identified.
Anemia in kidney disease is formally diagnosed when hemoglobin falls below 13 g/dL in men or below 12 g/dL in women, thresholds set by the World Health Organization and reaffirmed in the latest kidney disease guidelines. But symptoms can begin creeping in before hemoglobin drops to those cutoffs, especially in people who were previously active.
The Toll on the Heart
If EPO deficiency persists untreated, the cardiovascular system pays a steep price. When blood carries less oxygen, the heart compensates by pumping harder and faster. Over months and years, this extra workload causes the left ventricle (the heart’s main pumping chamber) to thicken and enlarge, a condition called left ventricular hypertrophy. This structural change is extremely common in people with chronic kidney disease and anemia.
The combination is dangerous. Research following kidney disease patients found that anemia alone raised the risk of serious cardiovascular events by about 50%. Left ventricular hypertrophy alone raised it by roughly 67%. But when both were present together, the risk of cardiac complications jumped to more than four times that of patients who had neither. This makes untreated EPO deficiency far more than a blood problem: it is a direct threat to heart health.
Why Kidney Disease Destroys EPO Production
In chronic kidney disease, the pericytes responsible for making EPO undergo a transformation. They change into scar-forming cells called myofibroblasts, part of the fibrosis that characterizes kidney damage. Once they’ve made this switch, they lose their ability to produce EPO. The worse the kidney scarring, the fewer functional EPO-producing cells remain. This is why anemia tends to worsen in lockstep with declining kidney function, and why it is nearly universal in people on dialysis.
Replacing What the Kidneys Can’t Make
The primary treatment for EPO deficiency is synthetic EPO, given by injection. These medications, known as erythropoiesis-stimulating agents, are lab-made versions of the same hormone healthy kidneys produce. The most widely used versions differ mainly in how long they last in the body. Shorter-acting forms need to be given three times per week, while longer-acting versions can be dosed once weekly or even less frequently. For people on hemodialysis, injections are typically given through the dialysis line.
These injections work well, but they have a critical requirement: iron. EPO tells the bone marrow to build red blood cells, but red blood cells need iron to carry oxygen. If your iron stores are depleted, which is common in kidney disease, the injections will not raise hemoglobin effectively. Doctors check iron levels before starting treatment and often prescribe iron supplements alongside EPO therapy. Functional iron deficiency, where the body has some iron stored but cannot mobilize it fast enough to keep up with accelerated red blood cell production, is a frequent obstacle.
Newer Oral Treatments
A newer class of medications takes a different approach entirely. Rather than injecting synthetic EPO from outside the body, these oral drugs trick the body’s own oxygen-sensing machinery into producing more EPO naturally, even from damaged kidneys or from the liver (which can make small amounts of EPO as a backup). They work by blocking the enzyme that normally breaks down HIF, the same oxygen-sensing protein that triggers EPO production in healthy kidneys. With HIF stabilized, the body ramps up its own EPO output and simultaneously improves iron absorption from the gut.
Several of these drugs have completed large clinical trials and received approval in various countries. They are taken as pills, which is a significant practical advantage over injections for people not yet on dialysis. They produce more modest, physiological increases in EPO compared to the sharp spikes that come with injections, which may translate to a more natural pattern of red blood cell production.
Life Without Any Intervention
Without treatment of any kind, complete EPO deficiency would lead to progressively worsening anemia. Hemoglobin would continue falling as old red blood cells die their natural deaths (roughly every 120 days) and too few replacements are produced. The body has limited compensatory tricks: it can increase heart rate, redirect blood flow to vital organs, and extract more oxygen from each red blood cell. But these mechanisms have limits. Severe untreated anemia causes organ damage, heart failure, and can be fatal. Before synthetic EPO became available in the late 1980s, people with kidney failure relied on frequent blood transfusions to survive, which carried their own risks of iron overload, infection, and immune reactions.